Cargando…

PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease

BACKGROUND: Autophagy is vital in the pathogenesis of neurodegeneration. Thus far, no studies have specifically investigated the relationship between pituitary adenylate cyclase-activating polypeptide (PACAP) and autophagy, particularly in the context of Alzheimer’s disease (AD). This study used in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qing, Wang, Yue, Li, Shiping, Shi, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605376/
https://www.ncbi.nlm.nih.gov/pubmed/37891608
http://dx.doi.org/10.1186/s13195-023-01334-2
_version_ 1785127058518573056
author Wang, Qing
Wang, Yue
Li, Shiping
Shi, Jiong
author_facet Wang, Qing
Wang, Yue
Li, Shiping
Shi, Jiong
author_sort Wang, Qing
collection PubMed
description BACKGROUND: Autophagy is vital in the pathogenesis of neurodegeneration. Thus far, no studies have specifically investigated the relationship between pituitary adenylate cyclase-activating polypeptide (PACAP) and autophagy, particularly in the context of Alzheimer’s disease (AD). This study used in vitro and in vivo models, along with clinical samples, to explore interactions between PACAP and autophagy in AD. METHODS: AD model mice were administered 6 μl of 0.1 mg/ml PACAP liquid intranasally for 4 weeks, then subjected to behavioral analyses to assess the benefits of PACAP treatment. The underlying mechanisms of PACAP-induced effects were investigated by methods including real-time quantitative polymerase chain reaction, RNA sequencing, immunofluorescence, and western blotting. Exosomes were extracted from human serum and subjected to enzyme-linked immunosorbent assays to examine autophagy pathways. The clinical and therapeutic implications of PACAP and autophagy were extensively investigated throughout the experiment. RESULTS: Impaired autophagy was a critical step in amyloid β (Aβ) and Tau deposition; PACAP enhanced autophagy and attenuated cognitive impairment. RNA sequencing revealed three pathways that may be involved in AD progression: PI3K-AKT, mTOR, and AMPK. In vivo and in vitro studies showed that sirtuin3 knockdown diminished the ability of PACAP to restore normal autophagy function, resulting in phagocytosis dysregulation and the accumulation of pTau, Tau, and Aβ. Additionally, the autophagic biomarker MAP1LC3 demonstrated a positive association with PACAP in human serum. CONCLUSIONS: PACAP reverses AD-induced cognitive impairment through autophagy, using sirtuin3 as a key mediator. MAP1LC3 has a positive relationship with PACAP in humans. These findings provide insights regarding potential uses of intranasal PACAP and sirtuin3 agonists in AD treatment. TRIAL REGISTRATION: NCT04320368. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01334-2.
format Online
Article
Text
id pubmed-10605376
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106053762023-10-28 PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease Wang, Qing Wang, Yue Li, Shiping Shi, Jiong Alzheimers Res Ther Research BACKGROUND: Autophagy is vital in the pathogenesis of neurodegeneration. Thus far, no studies have specifically investigated the relationship between pituitary adenylate cyclase-activating polypeptide (PACAP) and autophagy, particularly in the context of Alzheimer’s disease (AD). This study used in vitro and in vivo models, along with clinical samples, to explore interactions between PACAP and autophagy in AD. METHODS: AD model mice were administered 6 μl of 0.1 mg/ml PACAP liquid intranasally for 4 weeks, then subjected to behavioral analyses to assess the benefits of PACAP treatment. The underlying mechanisms of PACAP-induced effects were investigated by methods including real-time quantitative polymerase chain reaction, RNA sequencing, immunofluorescence, and western blotting. Exosomes were extracted from human serum and subjected to enzyme-linked immunosorbent assays to examine autophagy pathways. The clinical and therapeutic implications of PACAP and autophagy were extensively investigated throughout the experiment. RESULTS: Impaired autophagy was a critical step in amyloid β (Aβ) and Tau deposition; PACAP enhanced autophagy and attenuated cognitive impairment. RNA sequencing revealed three pathways that may be involved in AD progression: PI3K-AKT, mTOR, and AMPK. In vivo and in vitro studies showed that sirtuin3 knockdown diminished the ability of PACAP to restore normal autophagy function, resulting in phagocytosis dysregulation and the accumulation of pTau, Tau, and Aβ. Additionally, the autophagic biomarker MAP1LC3 demonstrated a positive association with PACAP in human serum. CONCLUSIONS: PACAP reverses AD-induced cognitive impairment through autophagy, using sirtuin3 as a key mediator. MAP1LC3 has a positive relationship with PACAP in humans. These findings provide insights regarding potential uses of intranasal PACAP and sirtuin3 agonists in AD treatment. TRIAL REGISTRATION: NCT04320368. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01334-2. BioMed Central 2023-10-27 /pmc/articles/PMC10605376/ /pubmed/37891608 http://dx.doi.org/10.1186/s13195-023-01334-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Qing
Wang, Yue
Li, Shiping
Shi, Jiong
PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
title PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
title_full PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
title_fullStr PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
title_full_unstemmed PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
title_short PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
title_sort pacap–sirtuin3 alleviates cognitive impairment through autophagy in alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605376/
https://www.ncbi.nlm.nih.gov/pubmed/37891608
http://dx.doi.org/10.1186/s13195-023-01334-2
work_keys_str_mv AT wangqing pacapsirtuin3alleviatescognitiveimpairmentthroughautophagyinalzheimersdisease
AT wangyue pacapsirtuin3alleviatescognitiveimpairmentthroughautophagyinalzheimersdisease
AT lishiping pacapsirtuin3alleviatescognitiveimpairmentthroughautophagyinalzheimersdisease
AT shijiong pacapsirtuin3alleviatescognitiveimpairmentthroughautophagyinalzheimersdisease